Therefore, although many challenges still remain and the therapeutic efficacy of various types of Tregs needs to be tested in pre-clinical models of MPO-AAV, cell therapy utilizing patients’ own ex vivo-modified Tregs, particularly antigen-specific ones, remains a promising potential treatment option for vasculitis patients worth further exploring. This evidence concerns the gene MPO and vasculitis.